Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Importance of Testing for CKD Among Patients With Type 2 Diabetes
Author(s): Pam Taub , Nikolaus Marx Added: 1 year ago
RP-UN-CAR-GB-0166 / June 2024This programme features a compelling discussion between two distinguished experts, Prof Pam Taub (University of California, San Diego, US) and Prof Nikolaus Marx (University Hospital RWTH, Aachen, DE), chairperson responsible for the most recent ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. Together, they delve into a critical… View more

Guidelines & Statements

Prevention & Chronic Conditions
ACC 26: SURPASS-CVOT - Tirzepatide vs Dulaglutide in T2D
Author(s): Steven E Nissen Added: 2 months ago
American College of Cardiology Congress 2026 – Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the effects of tirzepatide compared with dulaglutide on expanded cardiorenal outcomes from the SURPASS-CVOT trial (NCT04255433; Eli Lilly and Company).This international, double-blind, randomised, phase III cardiovascular outcomes trial enrolled 13,299 patients aged 40 and… View more

Cardiovascular Kidney Metabolic

Heart Failure
EASD 24: FINEARTS-HF: Diabetes Status Analysis
Author(s): John JV McMurray Added: 1 year ago
EASD 24 - We are joined by Professor John McMurray (University of Glasgow, UK) to discuss the key findings from a diabetes subgroup analysis of the FINEARTS-HF study.Interview Questions:1. What is the reasoning behind this analysis?2. What was the study design and patient cohort?3. What are the key findings?4. In your opinion, what can explain this risk reduction?5. What are the take-home… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
AHA 25 Late-breaking Discussion: Analysis from the SURPASS-CVOT Trial
Author(s): Harriette Van Spall , Stephen Nicholls Added: 6 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Stephen Nicholls (Monash University, AU) to present the findings of this AHA late-breaking trial.This pre-specified analysis of the SURPASS-CVOT randomised clinical trial evaluates the comparative effects of once-weekly tirzepatide versus dulaglutide on heart failure outcomes in… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
GLP-1RA in Different HFpEF Phenotypes
Author(s): Aleksandra Bykova , Maria Serova , Maria Chashkina , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Understanding the Role of GLP-1 RAs in the Treatment of HF
Author(s): Giovanni Battista Bonfioli , Matteo Pagnesi , Daniela Tomasoni , et al Added: 9 months ago

Cardiovascular Kidney Metabolic

Heart Failure
GLP-1RAs: Mechanism of Action and Role in HFpEF Management
Author(s): Magdy Abdelhamid , Mostafa M Abdrabou , Emanuel Faris , et al Added: 7 months ago

Heart Failure
ESC 24: FINE-HEART: Finerenone in HF & CKD
Author(s): Muthiah Vaduganathan Added: 1 year ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 1 year ago

Heart Failure
Finerenone: Will It Be a Game-changer?
Author(s): Dinesh Khullar , Anish Kumar Gupta , Kulwant Singh Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic